October 20, 2026 08:03 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Operation completed’: Tiger Shroff shooters allegedly alerted handlers after firing, probe reveals | 'I don't mind saying sorry 1,000 times': Sonu Nigam apologises to Kannadigas over ‘Pahalgam’ remark amid concert ban demand | After Vijay, is Dhanush eyeing politics? TVK calls Thalapathy an inspiration | Trump Says Paris Will Become ‘Muslim City Very Soon’, Blames Macron’s Immigration Policies | Four killed in fresh Manipur violence as protesters take bodies to Chief Minister’s residence | Tiger Shroff firing: Three accused arrested on train in Rajasthan, suspected Bishnoi gang link emerges | 'Internet access a fundamental right for children': SC rejects age-based 'blanket' ban | 'We will fight our own government': RG Kar victim's father threatens fresh protest after Sandip Ghosh gets bail | RG Kar shocker: Sandip Ghosh gets bail as only 7 of 147 witnesses examined, junior doctor blasts CBI | Trump waives Russia-related sanctions
Stock Market
Representational Photo: ChatGPT

Bloodbath on Dalal Street! Sensex crashes over 700 points, Nifty down 200 points amid market panic

| @indiablooms | Jan 08, 2026, at 02:08 pm

Mumbai/IBNS: The Indian stock market witnessed a sharp sell-off on Thursday, with the BSE Sensex plummeting over 700 points and the NSE Nifty 50 sliding more than 200 points, media reports said.

The indices remained under pressure throughout the morning session, with Sensex touching an intraday low of 84,230.

Among the notable laggards in the Nifty 500 were Signature Global, Hindustan Zinc, National Aluminium, NMDC, Hindustan Copper, JSL and GMDC.

At around 1:30 pm, Punjab National Bank shares fell 2.13%, while Apex Frozen Foods plunged 7.56%, intensifying the market slide.

In the morning, shares of Panacea Biotec Ltd. surged around 9 per cent on Thursday after the pharmaceutical and vaccine maker announced the completion of enrollment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll.

The company has enrolled a total of 10,335 participants in the late-stage trial, marking a key milestone in the development of India’s indigenous dengue vaccine.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.